Evidence mapPaperPMID 40551736Full record

ReviewFrontiers in nutrition2025

Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health.

Esteban Ortiz-Prado, Jorge Vasconez-Gonzalez, Juan S Izquierdo-Condoy, Isaac A Suárez-Sangucho, José Guillermo Prieto-Marín, Karen Bereniss Villarreal-Burbano, Mateo Alejandro Barriga-Collantes, John Alexander Altamirano-Castillo, Domenic Anahi Borja-Mendoza, Jean Carlo Pazmiño-Almeida and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Esteban Ortiz-PradoOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Jorge Vasconez-GonzalezOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Juan S Izquierdo-CondoyOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Isaac A Suárez-SanguchoOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
José Guillermo Prieto-MarínOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Karen Bereniss Villarreal-BurbanoOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Mateo Alejandro Barriga-CollantesOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
John Alexander Altamirano-CastilloOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Domenic Anahi Borja-MendozaOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Jean Carlo Pazmiño-AlmeidaOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
María Paz Cadena-PadillaOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D₃ (cholecalciferol) is a fat-soluble secosteroid with essential roles in calcium-phosphorus metabolism, bone health, and an expanding range of extraskeletal processes. Upon synthesis in the skin via ultraviolet B exposure or ingestion from dietary sources, cholecalciferol is hydroxylated in the liver and kidneys to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D), which exerts pleiotropic effects through vitamin D receptor (VDR)-mediated genomic and non-genomic pathways. This narrative review synthesizes evidence on the systemic effects of high-dose cholecalciferol on bone health, metabolism, cardiovascular and immune function, and its emerging roles in neurological, gastrointestinal, reproductive, oncologic, and psychiatric disorders. High-dose vitamin D₃ has demonstrated benefits in specific populations, including improved bone mineral density, immune homeostasis, glycemic control, and reduced inflammation. In patients with chronic kidney disease, cystic fibrosis, and inflammatory bowel disease, targeted supplementation has been associated with clinical improvements. Preclinical models support calcitriol's antiproliferative and neuroprotective functions, and its synergistic effects with chemotherapy, although large-scale randomized controlled trials (RCTs) have yielded mixed or inconclusive results, particularly in cancer, cardiovascular events, and cognitive decline. Methodological variability-such as inconsistent dosing regimens, baseline vitamin D status, and heterogeneous populations-limits definitive conclusions. While vitamin D supplementation is generally safe within recommended limits, excessive intake may cause hypercalcemia or nephrolithiasis, emphasizing the need for personalized strategies. Food fortification and targeted screening remain underutilized yet cost-effective public health interventions. Overall, vitamin D₃ represents a promising but complex therapeutic agent, necessitating further rigorously designed clinical trials to establish evidence-based guidelines for its use in diverse pathological conditions.

Indexed as

cholecalciferoleffects on healthhigh dosesvitamin Dvitamin D3

Identifiers

PMID40551736
PMCPMC12183072

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.